CClinicalTrials.gg
CompletedNCT05527314Updated Mar 24, 2023

Effect of Remimazolam vs Sevoflurane Anesthesia on Incidence of Emergence Agitation and Complications in Children Undergoing Ophthalmic Surgery

An interventional study of Remimazolam and Sevoflurane in Emergence Agitation, Remimazolam and Sevoflurane, sponsored by Second Affiliated Hospital of Nanchang University. Completed at 1 site in China. Open to participants aged 3 Years to 8 Years. Per ClinicalTrials.gov, last updated 2023-03-24.

Sponsored by Second Affiliated Hospital of Nanchang University · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
110
Allocation
Randomized
Ages
3 Years to 8 Years
Sex
All
01

Study summary

As a novel ultra-short-acting benzodiazepines drugs, Remimazolam has been accepted for induction and maintenance of clinical anesthesia. Compared to the traditional benzodiazepines drugs, Remimazolam combines the safety of midazolam with the effectiveness of propofol, and also has the advantages of acting quickly, short half-life, no injection pain, slight respiratory depression, independent of liver and kidney metabolism, long-term infusion without accumulation, and has a specific antagonist: flumazenil. This study aims to investigate whether Remimazolam reduces the incidence of emergence agitation in children after ophthalmic surgery, compared to sevoflurane (RCT).

02

Conditions studied

  • Emergence Agitation
  • Remimazolam
  • Sevoflurane
  • Pediatric Ophthalmic Surgery
  • Anesthesia, General

Keywords

  • Anesthesia, General
  • Pediatric ophthalmic surgery
  • Emergence Agitation
  • Remimazolam
  • Sevoflurane
03

In context

Psychomotor Agitation

500 studies on the registry are indexed under Psychomotor Agitation; 55 are open to participants now.

This study's enrollment of 110 is above the median of 90 across 413 interventional studies indexed under Psychomotor Agitation.

Browse Psychomotor Agitation studies →

Lead sponsor

Second Affiliated Hospital of Nanchang University is the lead sponsor of 78 studies on the registry; 47 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
3 Years to 8 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. ASA Ⅰ-Ⅱ
  2. Aged 3-8 years, weight > 10 kg, sex was not limited;
  3. Children were scheduled for selective ophthalmic surgery under general anesthesia,

Exclusion criteria

Exclusion Criteria:

  1. Respiratory infection was present within 4 weeks before surgery.
  2. Potential or presence of difficult airways, airway obstruction, sleep apnea, and other contraindications to general anesthesia.
  3. The blood routine or blood biochemical indexes were obviously abnormal.
  4. Allergy or hypersensitive reaction to test drug, including remimazolam, sevoflurane, and remifentanil.
  5. Any child who has taken benzodiazepines in the last 3 months.
  6. Unable to cooperate to complete the test, and the guardian refused to attend.
  7. Other reasons that researchers hold it is not appropriate to participate in this trial.
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
110 participants (actual)

Study arms

  • Experimental
    Remimazolam

    1. Induction of anesthesia Slowly inject Remimazolam 0.4-0.8 mg/kg (about 1 minute) until loss of consciousness (LoC), if the degree of sedation is insufficient, additional Remimazolam (0.05 mg/kg each time) is allowed. After the LoC, fentanyl 3-4 ug/kg and cisatracurium besilate 0.1 mg/kg are injected intravenously. After the muscles are sufficiently relaxed and blood circulation is stable, the tracheal tube is inserted under a glide scope. 2. Maintenance of anesthesia Remimazolam 1\~2 mg/kg/h and remifentanil 0.1\~0.3 ug/kg/min are injected intravenously to maintain sedation and assistant analgesia, and cisatracurium besilate 0.02 mg/kg is allowed to add as appropriate. During the operation, the dose of anesthetic drugs is adjusted so that the fluctuation of heart rate and blood pressure did not exceed 20 %.

    Drug: Remimazolam · Drug: Fentanyl · Drug: Cisatracurium Besylate · Drug: Remifentanil

  • Active comparator
    Sevoflorane

    1. Induction of anesthesia After the sevoflurane volatilization tank is adjusted to 8 % and the fresh gas flow rate is 5 L/min, the suitable mask connects with the outlet of the loop and covers the nose of the child. After the LoC, the sevoflurane volatilization tank is set to 3 % and the fresh gas flow rate is 2 L/min to maintain autonomous respiration. At the same time, fentanyl 3-4 ug/kg and cisatracurium besilate 0.1 mg/kg are injected intravenously. After the muscles are sufficiently relaxed and blood circulation is stable, the tracheal tube is inserted under a glide scope. 2. Maintenance of anesthesia Continuous inhalation of sevoflurane concentration 2 %-3 % and remifentanil 0.1-0.3 ug/kg/min intravenous pump to maintain sedation and assistant analgesia, and cisatracurium besilate 0.02 mg/kg is allowed to add as appropriate. During the operation, the dose of anesthetic drugs is adjusted so that the fluctuation of heart rate and blood pressure did not exceed 20 %.

    Drug: Sevoflurane · Drug: Fentanyl · Drug: Cisatracurium Besylate · Drug: Remifentanil

Interventions

  • DrugRemimazolam

    Anesthesia was induced with Remimazolam 0.4-0.8 mg/kg (about 1 minute) by intravenous injection until the loss of consciousness (LoC), followed by remimazolam 1-2 mg/kg/h until the end of surgery.

  • DrugSevoflurane

    Anesthesia was induced with 8 % Sevoflorane by sevoflurane volatilization tank until the loss of consciousness (LoC), followed by 2 %-3 % Sevoflorane until the end of surgery.

  • DrugFentanyl

    Anesthesia was induced with fentanyl 3-4 ug/kg by intravenous injection after the LoC.

  • DrugCisatracurium Besylate

    Anesthesia was induced with cisatracurium besilate 0.1 mg/kg by intravenous injection after the LoC. And the cisatracurium besilate 0.02 mg/kg is allowed to add as appropriate during the operation.

  • DrugRemifentanil

    After the LoC, remifentanil 0.1\~0.3 ug/kg/min inject intravenously until the end of surgery.

06

What researchers measure

Primary outcomes

  1. The incidence of emergence agitation

    The PAED scale consists of four items. Each item is scored 0-4 yielding a total between 0 and 20. The degree of emergence delirium increased directly with the total score. PAED scale \>12 at any time indicates presence of emergence agitation.

    Time frame: Duration from the time patients arrived the post-anesthesia care unit to the time of leaving to the ward, average 30 minutes

  2. The incidence of emergence agitation

    The Watcha scale consists of four items and scores \>2 at any time indicates presence of emergence agitation.

    Time frame: Duration from the time patients arrived the post-anesthesia care unit to the time of leaving to the ward, average 30 minutes

  3. The incidence of emergence agitation

    The 5-point scale consists of five items. The scores ≥4 and lasts for more than 5 minutes indicate presence of emergence agitation.

    Time frame: Duration from the time patients arrived the post-anesthesia care unit to the time of leaving to the ward, average 30 minutes

Secondary outcomes

  1. Systolic pressure

    "30 minutes before induction", "immediately after intubation", "every 5 minutes after intubation until the child leaves the post-anesthesia care unit and returns to the ward".

    Time frame: Up to 5 hours including preoperative, intraoperative, and postoperative periods

  2. Diastolic pressure

    "30 minutes before induction", "immediately after intubation", "every 5 minutes after intubation until the child leaves the post-anesthesia care unit and returns to the ward".

    Time frame: Up to 5 hours including preoperative, intraoperative, and postoperative periods

  3. Mean pressure

    "30 minutes before induction", "immediately after intubation", "every 5 minutes after intubation until the child leaves the post-anesthesia care unit and returns to the ward".

    Time frame: Up to 5 hours including preoperative, intraoperative, and postoperative periods

  4. Heart rate

    "30 minutes before induction", "immediately after intubation", "every 5 minutes after intubation until the child leaves the post-anesthesia care unit and returns to the ward".

    Time frame: Up to 5 hours including preoperative, intraoperative, and postoperative periods

  5. Recovery times

    The period from discontinuation of anesthetic drugs to the recovery of the child's self-consciousness and can respond correctly to external stimuli.

    Time frame: Up to 30 minutes after operation

  6. Delayed emergence

    Delayed emergence is defined as failure to shake hands and no significant response to nociceptive stimuli more than 30 minutes after surgery.

    Time frame: Up to 30 minutes after operation

  7. Postoperative Pain

    The FLACC scale consists of fIve items. Each item is scored 0-2 yielding a total between 0 and 10. The degree of pain increased directly with the total score.

    Time frame: During the recovery from anesthesia.

  8. Complication

    All the perioperative complications are recorded.

    Time frame: During the perioperative period

07

Study locations

1 site
  • the Second Affiliated Hospital of Nanchang University, Nanchang University
    Nanchang, Jiangxi, China
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 24, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05527314
Lead sponsor
Second Affiliated Hospital of Nanchang University
Responsible party
Fuzhou Hua (Chief Physician, Second Affiliated Hospital of Nanchang University) — Principal investigator
First posted
Sep 2, 2022
Start date
Aug 23, 2022
Primary completion
Feb 6, 2023
Completion
Feb 7, 2023
Last update
Mar 24, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion